Circassia Group Plc Settlement Agreement reached with Beyond Air (8038Z)
May 26 2021 - 01:00AM
UK Regulatory
TIDMCIR
RNS Number : 8038Z
Circassia Group Plc
26 May 2021
CIRCASSIA GROUP PLC
Settlement Agreement reached with Beyond Air
Oxford, UK - 26 May 2021: Circassia Group plc ("Circassia" or
"the Company"; AIM: CIR), a medical device company focused on
respiratory diagnostics and monitoring, today announces that it has
signed an agreement to settle its contractual dispute with Beyond
Air Inc. with regard to the licensing to Circassia by Beyond Air in
January 2019 of its LungFit (R) product (the "Settlement").
Under the terms of the original licence agreement, Circassia
issued $10.5 million of Circassia shares to Beyond Air during the
first half of 2019. Under the terms of the Settlement, Circassia
will surrender its rights to the LungFit (R) product in exchange
for payments by Beyond Air for up to a maximum of $16.5 million,
payable in cash as follows:
-- $2.5 million within 60 days of the approval of LungFit (R) by the FDA ("FDA approval")
-- $3.5 million within 60 days of the first anniversary of FDA approval
-- $4.5 million within 60 days of the second anniversary of FDA approval
Circassia will also be entitled to a further royalty of 5% of
net sales of LungFit (R), commencing on the second anniversary of
FDA approval and capped at a maximum of $6 million.
Ian Johnson, Circassia's Executive Chairman, said: "We are
pleased to have been able to resolve this dispute without recourse
to formal arbitration, with its associated long timescales and
significant legal expense."
This announcement contains inside information for the purposes
of the retained UK version of the EU Market Abuse Regulation (EU)
596/2014 ("UK MAR") and is disclosed in accordance with the
Company's obligations under UK MAR. This announcement is being made
on behalf of the Company by the directors named below.
Contacts
Circassia
Ian Johnson, Executive Chairman Tel: +44 (0) 1865 405 560
Michael Roller, Chief Financial Officer
N+1 Singer (Nominated Adviser and Broker)
Aubrey Powell/ Jen Boorer/ Hannah Woodley Tel: +44 (0) 20 7496
3000
About Circassia
Circassia is a medical device company focused on respiratory
diagnostics and monitoring. Our market-leading NIOX(R) products are
used in clinical settings by physicians around the world to help
improve asthma diagnosis and management and by leading research
organisations conducting clinical studies on behalf of
pharmaceutical companies. Customers are able to buy products and
receive customer service via dedicated teams in the United States,
UK, Sweden, Germany and China, on-line in some regions and our
network of global partners . For more information please visit
www.circassia.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRFFFSIETIEFIL
(END) Dow Jones Newswires
May 26, 2021 02:00 ET (06:00 GMT)
Circassia (LSE:CIR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Circassia (LSE:CIR)
Historical Stock Chart
From Mar 2023 to Mar 2024